Scarica l'app Stockscreener
6.42
3.72%
0.23
Dopo l'orario di chiusura:
6.42
Precedente Chiudi:
$6.19
Aprire:
$6.245
Volume 24 ore:
6.32M
Relative Volume:
2.34
Capitalizzazione di mercato:
$1.84B
Reddito:
$7.47M
Utile/perdita netta:
$-129.88M
Rapporto P/E:
-16.20
EPS:
-0.3962
Flusso di cassa netto:
$-115.33M
1 W Prestazione:
+15.05%
1M Prestazione:
+17.91%
6M Prestazione:
+17.80%
1 anno Prestazione:
+149.81%
Intervallo 1D:
$6.235
$6.5679
Intervallo di 1 settimana:
$5.545
$6.5679
Portata 52W:
$2.25
$7.30
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
6.42 | 1.84B | 7.47M | -129.88M | -115.33M | -0.3962 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies Inc (TSHA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Taysha Gene Therapies Inc (TSHA) Institutional Confidence - TradingKey
Taysha Gene Therapies Inc (TSHA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Taysha Gene Therapies Inc (TSHA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Taysha Gene Therapies Inc (TSHA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Taysha Gene Therapies Inc (TSHA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Taysha Gene Therapies Inc (TSHA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Taysha Gene Therapies Inc (TSHA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TSHA Gains Ground: Taysha Gene Therapies Approaches Key ResistanceLong Term Entry Picks - newsline.com
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery - Yahoo Finance
Taysha Therapeutics Shows High Bullish Potential as 2026 Catalysts Unfold - HarianBasis.co
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: Taysha Gene Therapies Q1 2026 misses EPS and revenue targets - Investing.com Nigeria
Taysha Gene Therapies Grants Restricted Stock Units and Stock Options to New Employees - Quiver Quantitative
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new Taysha hires get 714,700 RSUs and 468,600 options - Stock Titan
TSHA Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Cost ChallengesAnalyst Earnings Estimate - newsline.com
Taysha (TSHA) Q1 2026 Earnings Transcript - AOL.com
Taysha Gene Therapies Shareholders Back Governance and Leadership - TipRanks
Taysha (TSHA) director receives RSU and stock option awards, lifts holdings - Stock Titan
Taysha Gene Therapies (TSHA) director gets RSU and stock option grants - Stock Titan
Equity awards for Taysha (TSHA) director Alison S. Long detailed - Stock Titan
Taysha Gene Therapies (TSHA) director receives RSU and stock option grants - Stock Titan
Taysha Gene Therapies (NASDAQ: TSHA) holders approve board, auditor and annual say-on-pay - Stock Titan
Taysha Gene Therapies Inc Annual Shareholders Meeting Transcript - GuruFocus
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Taysha Gene Therapies: Shortened Timeline Increases The Potential (NASDAQ:TSHA) - Seeking Alpha
New Taysha Gene Therapies hires receive 349,000-share stock grant - Stock Titan
Taysha Gene Therapies stock hits all-time high at 5.49 USD - Investing.com Australia
Taysha Gene Therapies stock hits all-time high at 5.49 USD By Investing.com - Investing.com South Africa
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
Ontario girl with Rett Syndrome denied access to promising gene therapy trial, parents say - The Globe and Mail
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test By Investing.com - Investing.com Canada
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test - Investing.com
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Vestal Point and Ryan Wilder hold 6.3% of Taysha Gene Therapies (TSHA) - Stock Titan
RTW Investments and R. Wong report 20.7M shares in Taysha (NASDAQ: TSHA) - Stock Titan
Possible Bearish Signals With Taysha Gene Therapies Insiders Disposing Stock - Moomoo
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026 - Insider Monkey
TSHA-102 construct design study advances Rett syndrome research at ASGCT 2026 - Traders Union
Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event - Traders Union
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights - Insider Monkey
Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA - TipRanks
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 77% Upside in the Biotech Sector - DirectorsTalk Interviews
What Taysha (TSHA) is doing that changes everything (Pulls Back) 2026-05-08Long Setup Ideas - newsline.com
Taysha (TSHA) Advances Clinical Development Strategy for TSHA-10 - GuruFocus
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):